rAAV Purification via Affinity and Anion-Exchange Chromatography

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for purifying Adeno-Associated Virus (AAV) particles are not scalable, reproducible, or suitable for clinical use due to high contamination levels and the requirement for extensive pre-treatment steps, which hinders their application in gene therapy.

Innovation Solution

A multi-step purification method involving depth filtration, affinity chromatography, anion-exchange chromatography, and tangential flow filtration, which allows for the isolation of high-purity rAAV particles suitable for clinical applications without the need for extensive pre-treatment, such as treatment with detergents or nucleases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If extensive pre-treatment steps (detergents, nucleases, density gradient) are used, then purification effectiveness is improved, but process complexity and time are increased

Engineering Contradiction:
Improvepurification effectivenessVSAvoidprocess complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The purification process is divided into distinct modular steps: depth filtration step, affinity chromatography step, anion-exchange chromatography step, and tangential flow filtration step. Each step targets specific contaminants or purification objectives, allowing the complex purification task to be managed through sequential, specialized operations rather than one extensive pre-treatment procedure

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Depth filtration is performed as a preliminary step to remove cellular debris and large particles before chromatography steps. This preliminary action prevents clogging of chromatography columns and reduces the burden on subsequent purification steps, eliminating the need for extensive pre-treatment with detergents or nucleases

Inventive Principle:
Principle #10Preliminary action

2Manufacturing precision

If multiple purification steps are implemented, then purity is improved, but productivity is reduced

Engineering Contradiction:
ImprovepurityVSAvoidproduction efficiency
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The purification process is designed as a continuous flow where the output of one step becomes the input of the next without interruption. Depth filtration feeds directly into affinity chromatography, which feeds into anion-exchange chromatography, and finally into tangential flow filtration. This continuous operation maintains productivity while achieving high purity through multiple steps

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

Affinity chromatography serves as an intermediary step that selectively captures AAV particles from the complex cell lysate mixture. This intermediate purification step concentrates the target particles and removes major contaminants before the subsequent anion-exchange and tangential flow filtration steps, making the overall process more efficient

Inventive Principle:
Principle #24Intermediary (Mediator)

3Speed

If affinity chromatography is used, then purification speed is improved, but contamination by empty particles increases

Engineering Contradiction:
Improvepurification speedVSAvoidempty particle contamination
Core Design Contradiction:
SpeedVSManufacturing precision

Solution Approach 1:

The anion-exchange chromatography step specifically extracts and removes empty particles from the AAV preparation. By utilizing differences in surface charge between full and empty particles, this step separates the contaminating empty particles from the desired full particles, resolving the contamination issue introduced by the affinity chromatography step

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The process utilizes changes in ionic strength and pH conditions across different chromatography steps to differentially bind and elute full versus empty particles. Anion-exchange chromatography employs salt gradients that selectively elute empty particles at lower salt concentrations while full particles require higher salt concentrations, achieving separation based on physical-chemical parameter differences

Inventive Principle:
Principle #35Parameter changes

4Productivity

If scalable methods are developed, then productivity is improved, but manufacturing precision may be compromised

Engineering Contradiction:
ImprovescalabilityVSAvoidreproducibility
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The purification platform is designed with universal chromatography steps that can process different AAV serotypes and production scales using the same methodology. The depth filtration, affinity chromatography, anion-exchange chromatography, and tangential flow filtration steps form a scalable platform that maintains consistent purification performance whether processing small research-scale samples or large clinical-grade batches

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The process employs controlled parameter changes including pH adjustments, ionic strength gradients, and flow rate optimizations that can be precisely replicated across different scales. These parameter controls ensure reproducible separation and purification outcomes whether the process is run at pilot scale or full production scale, maintaining manufacturing precision while enabling scalability

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables the production of clinical-grade rAAV particles with high infectivity and purity, suitable for gene therapy, by effectively separating full and empty particles and reducing residual DNA levels, thus addressing the limitations of existing purification techniques.

Implementation Method 1

performing a depth filtration of a starting material previously obtained from cells producing rAAV particles

Methodology Applied
Scientific EffectDepth filtration: Filter (physical)

Implementation Method 2

submitting the rAAV-containing clarified composition to an affinity purification step

Methodology Applied
Scientific EffectAffinity purification: Adsorption

Implementation Method 3

submitting the first rAAV enriched composition at least once to: c1) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient

Methodology Applied
Scientific EffectAnion-exchange chromatography: Ion Exchange

Implementation Method 4

submitting the first rAAV enriched composition at least once to: c2) a step of density gradient centrifugation

Methodology Applied
Scientific EffectDensity gradient centrifugation: Centrifugal Separation

Implementation Method 5

submitting the second rAAV enriched composition to a step of tangential flow filtration

Methodology Applied
Scientific EffectTangential flow filtration: Filter (physical)

Data Source

PatentUS11021689B2Recombinant adeno-associated virus particle purification comprising an affinity purification step
Publication Date: 2021.06.01 NANTES UNIVERSITÉ (33 33)
  • US11021689B2 patent drawing
  • US11021689B2 patent drawing
  • US11021689B2 patent drawing

AI summary

The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising the steps of: a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being selected in a group comprising a cell lysate and a culture supernatant, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to an affinity purification step, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to: c1) a step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a salt gradient, preferably a linear salt gradient, and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; or c2) a step of density gradient centrifugation, wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.